MedImmune is recognized for outstanding efforts in implanting and improving waste reduction and recycling efforts with the Montgomery County 2010 Business Outstanding Achievement in Recycling Award from the Montgomery County Division of Solid Waste Services.
The U.S. Food and Drug Administration’s Antiviral Drugs Advisory Committee reviews MedImmune’s Motavizumab.
MedImmune names Ron Laufer, M.D. Senior Managing Director of MedImmune Ventures.
FDA resets its decision date for Motavizumab.
MedImmune presents “A Diamond in the Rough- Trends and Strategies in the Healthcare VC Market” at the 2010 Bio International Convention in Chicago, Illinois which explores current and future trends surrounding traditional and non-traditional investment funding.
At the 2010 Pediatric Academic Societies annual meeting in Vancouver, BC, Canada, MedImmune presents five abstracts in the area of respiratory syncytial virus (RSV).
MedImmune’s advocacy department launches Preemievoices.com, an online resource available for all those who touch and impact the lives of one of America’s most fragile patient population.
During the Annual Meeting for the American Association of Cancer Research, MedImmune showcases its commitment to cancer research with the presentation of ten abstracts on the progress that has been made in various oncology programs.
MedImmune presents ten abstracts on influenza at the 44 th National Immunization Conference, all of which add to the company’s growing body of research regarding pediatric infectious disease prevention.
MedImmune appoints Peter Greenleaf as new President.
Pediatrics: Official Journal of the American Academy of Pediatrics publishes pivotal results for MedImmune’s multinational, randomized, double-masked trial for motavizumab.
**
FluMist® Prescribing Information